Science

$Naveen Pemmaraju: Idarubicin and Cytarabine for patients with relapsed and/or refractory AML$

Naveen Pemmaraju/mdanderson.org

Apr 20, 2025, 12:33

Naveen Pemmaraju: Idarubicin and Cytarabine for patients with relapsed and/or refractory AML

Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Our group’s new article led by Dr Hannah Goulart and Dr Tapan Kadia Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia (AML).”

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.

Authors: Hannah Goulart, et al.

$Naveen Pemmaraju: Idarubicin and Cytarabine for patients with relapsed and/or refractory AML$

Acute Myeloid Leukemia AML BPDCN Program cancer Cladribine CLIA cytarabine fight against cancer Global fight against cancer Hannah Goulart idarubicin MD Anderson Cancer Center Naveen Pemmaraju OncoDaily Oncology Tapan Kadia University of Texas

Padraic O’Malley: Meet the Experts of VIRO 2025

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

FDA Breakthrough Therapy Designation for Iza-bren: Advancing Treatment for EGFR-Mutant NSCLC

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen